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Abstract 
 
Merkel cell polyomavirus (MCPyV) has been identified in samples of Merkel cell carcinoma (MCC), an aggressive skin cancer. 
Seroepidemiologic studies indicated a high frequency of MCPyV infection in humans, suggesting respiratory and faecal–oral 
routes, or transmission by skin contact. Since MCC is more frequent in immunocompromised patients, a reactivation of 
MCPyV latently infecting target cells has been proposed. However, neither definite ways of transmission nor specific target 
organs have been identified with certainty. Ten autopsies with an extensive organ sampling for a total of 121 specimens 
(tissue and blood samples) were collected. All tissue specimens were fixed in formalin and embedded in paraffin. Real-time 
PCR was performed to quantify the copy number of the large T antigen (LT) gene and the capsid VP1 gene of MCPyV. MCPyV 
LT and/or VP genes were detected in all of the collected specimens. A high prevalence of MCPyV was found in the blood (six 
cases) and lung (five cases); the brain was positive in three cases. The highest viral copy number was detected in blood from 
two autopsies (21 610 570.09 copies per 105 cells and 380 413.25 copies per 105 cells), whereas the viral copy number in the 
other organs was low. Our data confirm the high frequency of MCPyV infection in the general population, which seems to 
indicate that the respiratory tract is a possible route for viral transmission and viral persistence in the brain. The frequent 
detection of MCPyV DNA in blood suggests that circulating leukocytes could be one of the reservoirs of MCPyV, whereas the 
high viral copy number also seems to indicate the possibility of viral reactivation in immunocompetent adults. 
 
 
INTRODUCTION 
Merkel cell polyomavirus (MCPyV) is a recently discovered 
human polyomavirus, identified by digital transcriptome 
subtraction in samples of Merkel cell carcinoma (MCC) [1]. 
MCC is a rare and very aggressive human skin cancer; its 
incidence is higher among immunocompromised patients 
and elderly people than in the general population, suggest-
ing a possible mechanism of reactivation of MCPyV latently 
infected target cells, favoured by an impairment of immune 
surveillance [2]. A study by Nicol et al. [3] showed that the 
seroprevalence of MCPyV was 85 % in the adult healthy 
population and 58 % in children less than 10 years of age, 
indicating that primary exposure to MCPyV infection 
occurs frequently in early childhood. 
Possible sites of viral persistence have been investigated in 
body fluids [4, 5], tissue biopsies [6] and surgical specimens 
from several organs [7], but to the best of our knowledge, 
only one study has investigated the distribution of MCPyV 
in autopsy cases in Japan [8]. Therefore, more systematic 
studies searching for MCPyV DNA in human tissues are 
needed to elucidate the possible anatomical sites of 
viral persistence. 
Our study aimed to investigate the presence of MCPyV 
DNA in several organs from 10 complete autopsies, in order 
to identify the prevailing sites of viral persistence and con-
tribute to comprehension of the mechanisms of 
MCPyV transmission. 
 
RESULTS 
The main demographic data and causes of death are shown 
in Table 1. There were four females and six males, with nine 
Caucasians and one South American. The mean age was 
67.9 years (range, 30–90 years) and the causes of death 
included cardiovascular or respiratory diseases (four cases) 
and septic or haemorrhagic shock (six cases). 
A total of 121 specimens (111 tissue and 10 whole blood 
samples) taken during the autopsies were obtained from an 
extensive sampling (Table 2). 
 
 
  
Table 1. Main demographic data and causes of death 
 
Autopsy no./sex/age (years) Country Interval death–autopsy (hours) Cause of death Main pathologies 
1/M/77 Italy 72 Heart failure Cardiovascular disease 
2/F/70 Albania 48 Haemorrhagic shock None 
3/F/72 Italy 48 Septic shock Diverticular disease, with perforation 
4/F/70 Italy 48 Septic shock Cytomegalovirus colitis 
5/M/71 Italy 48 Respiratory and heart failure Coronary artery disease 
6/M/66 Italy 48 Cardiogenic shock Cardiovascular disease 
7/M/56 Italy 72 Acute respiratory distress syndrome Aortic aneurysm 
8/M/30 Brazil 72 Haemorrhagic shock None 
9/F/90 Italy 48 Pulmonary thromboembolism; Generalized vasculopathy 
heart failure 
10/M/77 Italy 72 Septic shock Chronic leishmaniasis 
M, male; F, female 
 
 
Genomic sequences of LT, VP or both regions of MCPyV 
were detected in all cases in at least one sample. In detail, 
viral DNA was detected in samples from five organs in 
two cases (in autopsies nos7 and #10), from four organs in 
three cases (in autopsies #2, #4 and #9) and from one 
organ in four cases (in autopsies #1, #5 and #6) (see 
Table 3). 
A high prevalence of MCPyV DNA was found in the blood 
(six cases) and lung (five cases), and low prevalence was 
found in the small bowel, liver and ovary (one case each). 
Viral DNA was also detected in the stomach (three cases), 
heart (three cases), skin (three cases), brain (three cases) 
and bladder (two cases). Uterus and prostate specimens 
were always negative. 
The copy number of the MCPyV LT and VP1 was calcu-
lated among different organs and within a single autopsy 
case (Table 3). The highest copy number was detected in 
autopsies #7 and #9, in which blood samples had 
 
 
Table 2. Distribution of MCPyV in organs/whole blood 
Organ (no.) VP1 (%) LT (%) VP1 and MCPyV (%) 
LT (%) 
 
Brain (n=10) 1 (10) 2 (20) 0 3 (30) 
Heart (n=10) 1 (10) 2 (20) 0 3 (30) 
Liver (n=10)                       0 1 (10) 0 1 (10) 
Small bowel (n=10) 1 (10)             0 0 1 (10) 
Spleen (n=10)                     0                0 0                    0 
Lung (n=10) 3 (30) 2 (20) 0 5 (50) 
Kidney (n=10) 2 (20) 1 (10)         1 (10) 4 (40) 
Bladder (n=10) 1 (10)             0             1 (10) 2 (20) 
Skin (n=10) 3 (30)             0 0 3 (30) 
Stomach (n=10) 3 (30)             0 0 3 (30) 
Uterus (n=3)                      0                0 0                    0 
Ovary (n=3)                       0           1 (33.3) 0               1 (33.3) 
Prostate (n=5)                    0                0 0                    0 
Whole blood (n=10) 1 (10) 3 (30)         2 (20) 6 (60) 
21 610 570.09 copiesper 105 cells and 380 413.25 copies 
per 105 cells, respectively. Interestingly, autopsy #7 had a 
high MCPyV copy number in the skin, suggesting the possi-
bility of viral replication in skin, followed by a viraemic 
phase. Moreover, autopsy #9 had a high copy number in the 
brain sample (5051.32 copies per 105 cells) and in the ovary 
(369.81 copiesper 105 cells), but the skin sample was 
negative. The copy number of MCPyV was low in eight 
autopsies and in most of the organs examined (Table 3), 
suggesting a high frequency of viral persistence. 
 
Tissue samples with MCPyV LT DNA that was detectable 
by molecular analysis were submitted to immunohis-
tochemistry for MCPyV T antigen detection. None of the 
samples tested positive. 
 
DISCUSSION 
Epidemiological studies have shown the high frequency of 
MCPyV exposure in the human population [9–11], similar to 
other members of the Polyomaviridae family [12, 13]. In most 
of the cases, the primary infection occurs during childhood 
and reaches 85 % in adulthood [10], as demonstrated by the 
presence of antibodies against MCPyV antigens in serum 
samples of healthy adults [3]. Moreover, sustained MCPyV-
specific antibody titres may indicate a persistent infection or 
viral latency within several target organs and tissues. 
A few works have reported the detection of genomic 
sequences of MCPyV in the respiratory tract and saliva [7, 
14, 15], the gastrointestinal tract [16], lymphoid tissue [17] 
and skin [1]. 
Several means of transmission have been hypothesized, 
such as a respiratory route [18], a faecal–oral route [7, 16] 
and shedding of viral particles from the skin [19], although 
none of these has been confirmed with certainty. 
In this work, we evaluated the presence and quantity of 
MCPyV LT and VP1 DNA sequences in different organs and 
whole blood from 10 autopsies. The causes of death were car-
diovascular/respiratory diseases or septic and haemorrhagic 
 
 
  
Table 3. MCPyV copy number (copies per 105 cells) in organs and whole blood from 10 autopsies 
 
Organs and Blood 
 
Autopsy Brain Heart Liver Small Lung Kidney Bladder Skin Stomach Ovary Whole blood 
no.                                                                          bowel 
1                         0               0              0                0               0             3.94L |                  0                      0                    0               0                        0 
0.0044V 
2 42.92L 134.84L 0 0 12.9L 0 0 0 0.28V 0 0 
3 0 0 0 0 0 0 0 0 0 0 1.82L | 80.79V 
4 0.07V 0 0 0 0 0.08V  50.4L | 0 0.05V 0 2124.63L 
0.087V 
5 0 0 0 0 0 0 0 57.63V 0 0 0 
6 0 0 0 0 0.37V 0 0 0 0 0 0.00089V 
7 0 1.26V 0 10.46V 1.53V 2.1V 0 192 251 0 0 64.58L | 21 610 
784.0V                                                                               570.09V 
8 0 0 0 0 0 0 0 12.06V 0 0 1433.3L 
9 5051.32L 0 0 0 99.0L 0 10.41V 0 0 369.81L 380 413.25L 
10                       0            4.22L          10.71L 0            0.01V                17.1L                            0 0                 0.09V                  0                        0 
L,MCPyV LT; V, MCPyV VP1 
 
 
shock. None of the subjects had known causes of immunosup-
pression. An extensive sampling of organs and tissues was pe
r-formed for a total of 121 specimens. 
Our results confirm the high frequency of MCPyV exposure 
in the general population. Indeed, LT and/or VP1 genomic 
sequences were detected at least in one sample of all the auto
p-
sies examined. It is worth underlining that in most of the posi-
tive cases we only detected LT or VP1 genomic sequences, 
and we rarely detected both; this could be explained by viral 
DNA degradation in autopsy specimens occurring in the 
interval between death and autopsy and by the different 
amplicon lengths (59 bp for VP1, 146 bp for LT). 
MCPyV DNA was found in a wide variety of organs and 
apparatus; notably, lung tissues disclosed the highest preva-
lence of viral DNA (5 of 10 cases). Since in two of these 
cases matched blood samples were MCPyV DNA-negative, 
the possibility of blood contamination by circulating viral 
DNA could be excluded. Babakir-Mina et al. [18], identified 
MCPyV DNA in 5 (17.24 %) out of 87 lower respiratory 
tract samples, which suggests that the virus may be trans-
mitted through the respiratory route and then, after spread-
ing in the body, may undergo low-level replication and 
persistence or may establish latency in other anatomical 
sites. The results of our study seem to support Babakir-
Mina’s hypothesis: viral DNA was detected in lung samples 
from five autopsies, and all cases showed viral DNA in sev-
eral organs or in matched blood samples. 
Another interesting result of our study was the detection of 
MCPyV DNA in brain samples from three autopsies. To the 
best of our knowledge, this is the first study to report this 
finding. Lam et al. [20] studied 300 brain samples from 30 
autopsies of unselected individuals to search for the human 
polyomaviruses BK, JC, KI, WU and MCPyV by means of 
nested PCR, and no samples tested positive for MCPyV 
DNA [20]. Methodological differences and pre-analytical 
processing of the samples may explain the fact that the 
results for the rate of detection of MCPyV DNA obtained in 
the study by Lam et al. [20] and the present study differ. 
Indeed, the quality and method of fixation may influence 
the rate of viral detection, while low levels of viral DNA can 
be undetectable when using lower sensitivity DNA amplifi-
cation methods. Matsushita et al. [8] performed an analysis 
of 41 autopsies and did not find genomic sequences of 
MCPyV in brain tissue. Notably, in our study, viral DNA 
was detected in brain autopsy specimens with positive and 
negative matched blood samples, avoiding the possibility of 
cross-contamination with blood included in paraffin 
blocks. Similar to other members of the Polyomaviridae 
family, such as JC virus and BK virus, that have been 
reported to infect brain tissue at some frequency, it is con-
ceivable that MCPyV could also target brain cells, remain-
ing in a latent state during the lifetime of the host. 
In our study, skin samples were positive in three cases. This 
finding is slightly different from the results of Matsushita et al. 
[8] and Loyo et al. [7], which reported a prevalence of MCPyV 
DNA of about 50 % in autopsies and surgical samples of skin, 
including non-neoplastic skin biopsies. Moreover, the detec-
tion of MCPyV on environmental surfaces in contact with 
human skin [7] suggests that this virus is part of the normal 
microflora of the skin and viral particles could be transmitted 
by direct or indirect contact with human skin. Oh et al. [21], 
by using a metagenomic sequencing approach, demonstrated 
that MVPyV, like other microorganisms, tended to be stable 
over time on skin surface. In our study, the relatively low prev-
alence of MCPyV detection could be tentatively explained by 
the degradation of viral genome or the detachment of viral 
particles from skin after death. 
MCPyV DNA was detected in whole blood from six autop-
sies. All the samples were taken during autopsy, and separa-
tion of plasma or serum from whole blood was technically 
 
 not possible, therefore we were not able to identify the 
source of the viral DNA. Pancaldi et al. [22] identified 
MCPyV DNA in the buffy coats of healthy donors, indicat-
ing a possible infection of leukocytes and suggesting that 
these cells are a possible viral reservoir in a fraction of 
healthy subjects. Interestingly, in two blood samples we 
found a very high copy number of MCPyV, indicating viral 
reactivation followed by a viremia. The two subjects were 
dead from cardiovascular diseases and no causes of immu-
nosuppression were reported by clinicians. We speculated 
that MCPyV could also reactivate in conditions of stress, or 
in minor immunosuppressive states. Alternatively, the 
higher viral copy number detected in blood, compared to 
the formalin-fixed paraffin-embedded (FFPE) tissue speci-
mens from autopsies, could also be due to the better preser-
vation of DNA in blood samples. 
Our quantitative data obtained by real-time PCR indicated 
that MCPyV DNA was present at a low copy number in most 
of the tissues, excluding blood samples and the skin sample in 
autopsy #7. These data suggest that MCPyV DNA may persist 
in several human tissues during life. Different positivity cut-
offs, either for MCPyV or for other members of the polyoma 
virus family, have been reported in the literature, depending 
on the methodology used. According to Bhatia et al. [23], who 
used qRT-PCR, our samples were considered positive for 
MCPyV DNA detection when amplicons were generated 
within the range of 40 cycles. Accordingly, a very small 
amount of viral DNA was expected in cases with low levels of 
viral replication or tissue persistence. 
The main limit was the low number of cases included in this 
study, which did not allow definite conclusions about the tis-
sue distribution of MCPyV in adult populations to be drawn. 
However, these observational data seem to indicate a high 
prevalence of MCPyV DNA in the respiratory tract and dem-
onstrate the possibility of viral persistence in circulating leuko-
cytes and the central nervous system. Further research in 
larger autopsy series is needed to confirm our findings. 
 
METHODS 
Clinical specimens 
Tissue samples were obtained from 10 autopsies, performed 
consecutively from April 2015 to September 2015. The 
interval between death and the execution of the autopsy was 
48–72 h. The samples were obtained from brain, lung, kid-
ney, heart, liver, spleen, bladder, stomach, small intestine, 
skin, prostate, ovary and uterus for a total of 111 samples. 
In all 10 autopsy cases, whole blood samples were collected 
into EDTA tubes. Autopsy specimens were immediately 
fixed in 10 % neutral buffered formalin for a minimum of 
48 h and embedded in paraffin. Three-micrometre-thick 
sections of FFPE tissues were stained with haematoxylin 
and eosin (H and E) and examined by light microscopy. 
 
DNA preparation 
Genomic DNA was isolated from three to five (5-µm thick) 
sequential sections of FFPE tissues using a QIAamp DNA 
FFPE kit (Qiagen, Germany), and extraction was performed 
by QIACUBE (Qiagen). To avoid cross-contamination of 
samples, the microtome blade was cleaned with xylene 
between each block. The DNA extraction from 200 µl whole 
blood was performed using NucleoSpin Blood (Machery-
Nagel, Germany) according to the manufacturer’s protocol. 
The b-actin gene was amplified in all cases and used as a 
positive control for DNA extraction by qualitative PCR. The 
b-actin primers were forward primer 5¢-CCTTCC 
TGGGCATGGAGTCCTG-3¢ and reverse primer 5¢-
GGAGCAATGATCTTGATCTTC-3¢ [amplification prod-
uct of 202 base pairs (bp)]. PCR products were analysed 
using agarose gel electrophoresis (2 %). 
 
Detection and quantification of MCPyV DNA 
The primers targeting the LT and the VP1 genes of MCPyV 
(Table 4) were used according to the method described by 
Goh et al. [14], with modifications. Briefly, each 10 µl reac-
tion mixture contained 1.6 µl (100 ng µl 1) of genomic 
DNA, 6 µl of TaqMan Universal PCR Master mix (Applied 
Biosystems, USA), 800 nM of LT primers or 450 nM of VP1 
primers and 320 nM of LT probe or 450 nM of VP1 probe. 
The thermal cycling conditions were as follows: 50 C for 
2 min, 95 C for 10 min, followed by 40 cycles of 95 C for 
5s and 60 C (LT assay) or 58 C (VP1 assay) for 1 min. 
Real-time PCR was performed on the 7500 Fast Real-Time 
PCR system (Applied Biosystems, USA). 
 
The pCR.MCV350 plasmid described by Feng et al. [1] was 
used as the template to prepare the standard curve for the 
real-time PCR assay and analyse assay sensitivity. The stan-
dard curves used to quantify the MCPyV LT or VP1 copy 
number were made with five serial dilutions (1 : 10) of the 
plasmid, ranging from 300 000 to 30 copies. MCPyV LT or 
VP1 copy numbers were normalized to the amount of cellu-
lar DNA by the quantification of human RNAse P copies 
and were expressed as number of copies per 105 cells. The 
standard curve used for the human RNAse P gene quantifi-
cation was made according to the manufacturer’s instruc-
tions with five serial dilutions (1 : 10) of calibrated human 
genomic DNA, ranging from 100 000 to 10 copies ml 1 of 
RNAse P (TaqMan RNAse P Detection Reagents Kit, 
Applied Biosystems, USA). The standard curve, with no 
template control (nuclease-free water), and samples were all 
tested in triplicate. Samples were considered positive for 
MCPyV DNA detection when amplicons were generated 
within the range of 40 cycles. 
 
Immunohistochemistry 
To estimate the expression of MCPyV T antigen protein, 
3 µm-thick FFPE tissue sections were stained with a mono-
clonal antibody, CM2B4 (Santa Cruz Biotechnology, USA). 
Immunohistochemical staining was performed on a Dako 
Autostainer (Dako, Germany) following the manufacturer’s 
instructions. Briefly, the slides were deparaffinized and 
hydrated, and antigen retrieval was performed using Tris-
EDTA buffer (pH 8) in a microwave oven for 14 min (750 
W). Endogenous peroxidase activity was blocked using 
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Table 4. Primers and probes used for the LT and VP1 regions of 
MCPyV, real-time PCR 
Primer/probe                          Sequence (5¢ﬁ 3¢)                         Amplicon 
size (bp) 
MCPyV LT 146 
LT forward         CCACAGCCAGAGCTCTTCCT 
LT reverse TGGTGGTCTCCTCTCTGCTACTG 
LT probe FAM-TCCTTCTCAGCGTCCCAGGC 
TTCA-TAMRA 
MCPyV VP1 59 
VP1 forward TGCCTCCCACATCTGCAAT 
VP1 reverse GTGTCTCTGCCAATGCTAAATGA 
VP1 probe 6FAM-TGTCACAGGTAATATC-
MGBNFQ 
 
 
hydrogen peroxide 3 % for 10 min. Specimens were then 
incubated with primary antibody (at a dilution of 1 : 50) for 
30 min at room temperature. After washing, specimens were 
incubated for 30 min with Dako Envision + Dual Link at 
room temperature for subsequent deaminobenzidine (DAB) 
reaction. Positive controls from previously tested MCPyV 
samples, consisting of Merkel cell carcinoma tissue, were 
used in every immunohistochemistry session. All slides 
were counterstained with haematoxylin and protected with 
a coverslip for microscopic examination. 
 
 
Funding information 
This research received no specific grant from any funding agency in 
the public, commercial, or not-for-profit sectors. 
 
Conflicts of interest 
The authors declare that they have no conflicts of interest. 
 
Ethical statement 
All the patients’ relatives gave informed consent for the diagnostic and 
scientific use of tissue (and blood) samples taken during autopsies. 
This study was approved by the Medical Ethical Committee of the Hos-
pital ‘Maggiore della Carita’ of Novara. 
 
References 
1. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a poly-
omavirus in human Merkel cell carcinoma. Science 2008;319: 
1096–1100. 
2. Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel 
cell carcinoma and HIV infection. The Lancet 2002;359:497–498. 
3. Nicol JT, Robinot R, Carpentier A, Carandina G, Mazzoni E et al. 
Age-specific seroprevalences of Merkel cell polyomavirus, human 
polyomaviruses 6, 7, and 9, and trichodysplasia spinulosa-associ-
ated polyomavirus. Clin Vaccine Immunol 2013;20:363–368. 
4. Signorini L, Belingheri M, Ambrogi F, Pagani E, Binda S et al. 
High frequency of Merkel cell polyomavirus DNA in the urine of 
kidney transplant recipients and healthy controls. J Clin Virol 
2014;61:565–570. 
5. Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y et al. 
Quantitation of human seroresponsiveness to Merkel cell poly-
omavirus. PLoS Pathog 2009;5:e1000578. 
6. Bergallo M, Costa C, Terlizzi ME, Astegiano S, Curtoni A et al. 
Quantitative detection of the new polyomaviruses KI, WU and Mer-
kel cell virus in transbronchial biopsies from lung transplant 
recipients. J Clin Pathol 2010;63:722–725. 
7. Loyo M, Guerrero-Preston R, Brait M, Hoque MO, Chuang A et al. 
Quantitative detection of Merkel cell virus in human tissues and 
possible mode of transmission. Int J Cancer 2010;126:2991–2996. 
8. Matsushita M, Kuwamoto S, Iwasaki T, Higaki-Mori H, Yashima S 
et al. Detection of Merkel cell polyomavirus in the human tissues 
from 41 Japanese autopsy cases using polymerase chain reac-
tion. Intervirology 2013;56:1–5. 
9. Carter JJ, Paulson KG, Wipf GC, Miranda D, Madeleine MM et al. 
Association of Merkel cell polyomavirus-specific antibodies with 
Merkel cell carcinoma. J Natl Cancer Inst 2009;101:1510–1522. 
10. Touze A, Gaitan J, Arnold F, Cazal R, Fleury MJ et al. Generation 
of Merkel cell polyomavirus (MCV)-like particles and their applica-
tion to detection of MCV antibodies. J Clin Microbiol 2010;48:1767– 
1770. 
11. Faust H, Pastrana DV, Buck CB, Dillner J, Ekström J. Antibodies 
to Merkel cell polyomavirus correlate to presence of viral DNA in 
the skin. J Infect Dis 2011;203:1096–1100. 
12. Viscidi RP, Rollison DE, Sondak VK, Silver B, Messina JL et al. 
Age-specific seroprevalence of Merkel cell polyomavirus, BK 
virus, and JC virus. Clin Vaccine Immunol 2011;18:1737–1743. 
13. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepi-
demiology of the human polyomaviruses. J Gen Virol 2003;84: 
1499–1504. 
14. Goh S, Lindau C, Tiveljung-Lindell A, Allander T. Merkel cell poly-
omavirus in respiratory tract secretions. Emerg Infect Dis 2009;15: 
489–491. 
15. Bialasiewicz S, Lambert SB, Whiley DM, Nissen MD, Sloots TP. 
Merkel cell polyomavirus DNA in respiratory specimens from chil-
dren and adults. Emerg Infect Dis 2009;15:492–494. 
16. Campello C, Comar M, D’Agaro P, Minicozzi A, Rodella L et al. A 
molecular case-control study of the Merkel cell polyomavirus in 
colon cancer. J Med Virol 2011;83:721–724. 
17. Shuda M, Arora R, Kwun HJ, Feng H, Sarid R et al. Human Merkel 
cell polyomavirus infection I. MCV T antigen expression in Merkel 
cell carcinoma, lymphoid tissues and lymphoid tumors. Int J 
Cancer 2009;125:1243–1249. 
18. Babakir-Mina M, Ciccozzi M, Lo Presti A, Greco F, Perno CF et al. 
Identification of Merkel cell polyomavirus in the lower respiratory 
tract of italian patients. J Med Virol 2010;82:505–509. 
19. Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB. 
Merkel cell polyomavirus and two previously unknown polyomavi-
ruses are chronically shed from human skin. Cell Host Microbe 
2010;7:509–515. 
20. Lam WY, Leung BW, Chu IM, Chan AC, Ng HK et al. Survey for the 
presence of BK, JC, KI, WU and Merkel cell polyomaviruses in 
human brain tissues. J Clin Virol 2010;48:11–14. 
21. Oh J, Byrd AL, Park M, NISC Comparative Sequencing Program, 
Kong HH et al. Temporal stability of the human skin microbiome. 
Cell 2016;165:854–866. 
22. Pancaldi C, Corazzari V, Maniero S, Mazzoni E, Comar M et al. 
Merkel cell polyomavirus DNA sequences in the buffy coats of 
healthy blood donors. Blood 2011;117:7099–7101. 
23. Bhatia K, Goedert JJ, Modali R, Preiss L, Ayers LW. Merkel cell 
carcinoma subgroups by Merkel cell polyomavirus DNA relative 
abundance and oncogene expression. Int J Cancer 2010;126:2240– 
2246. 
 
 
 
 
 
 
 
